BNF:

8.2.4

Status:

Red

Decision Date:

None

Comments

RED^1,2: NICE TA624 - Beta 1a (Plegridy) indicated for relapsing-remitting multiple sclerosis in adults (Decision date - March 2020)

RED^1,2,3,8: NICE TA527 - Beta interferons (beta-1a (Avonex & Rebif) & beta-1b (Extavia)) and glatiramer acetate for treating multiple sclerosis (Decision date - July 2018)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again